![]() |
|
|
Vol. 27, Issue 12, 1434-1447, December 1999
Departments of Drug Metabolism and Pharmacokinetics (P.S.R.,
D.P.J., J.J.K., S.E.H.) and Analytical Sciences (R.M.D., W.C.D.),
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield,
Connecticut
The study objectives were to characterize the metabolism of
nevirapine (NVP) in mouse, rat, rabbit, dog, monkey, and chimpanzee after oral administration of carbon-14-labeled or -unlabeled NVP. Liquid scintillation counting quantitated radioactivity and bile, plasma, urine, and feces were profiled by HPLC/UV diode array and
radioactivity detection. Metabolite structures were confirmed by UV
spectral and chromatographic retention time comparisons with synthetic
metabolite standards, by
-glucuronidase incubations, and in one
case, by direct probe electron impact ionization/mass spectroscopy,
chemical ionization/mass spectroscopy, and NMR. NVP was
completely absorbed in both sexes of all species except male and female
dogs. Parent compound accounted for <6% of total urinary
radioactivity and <5.1% of total fecal radioactivity, except in dogs
where 41 to 46% of the radioactivity was excreted as parent compound.
The drug was extensively metabolized in both sexes of all animal
species studied. Oxidation to hydroxylated metabolites
occurred before glucuronide conjugation and excretion in urine
and feces. Hydroxylated metabolites were 2-, 3-, 8-, and
12-hydroxynevirapine (2-, 3-, 8-, and 12-OHNVP). 4-carboxynevirapine, formed by secondary oxidation of 12-OHNVP, was a major urinary metabolite in all species except the female rat. Glucuronides of the
hydroxylated metabolites were major or minor metabolites, depending on
the species. Rat plasma profiles differed from urinary profiles with
NVP and 12-OHNVP accounting for the majority of the total
radioactivity. Dog plasma profiles, however, were similar to the
urinary profiles with 12-OHNVP, its glucuronide conjugate, 4-carboxynevirapine, and 3-OHNVP glucuronide being the major
metabolites. Overall, the same metabolites are formed in animals as are
formed in humans.
This article has been cited by other articles:
![]() |
M. Qian, S. A. Bai, B. Brogdon, J.-T. Wu, R.-Q. Liu, M. B. Covington, K. Vaddi, R. C. Newton, M. J. Fossler, C. E. Garner, et al. Pharmacokinetics and Pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-Amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a Potent and Selective Inhibitor of Tumor Necrosis Factor {alpha}-Converting Enzyme in Rodents, Dogs, Chimpanzees, and Humans Drug Metab. Dispos., October 1, 2007; 35(10): 1916 - 1925. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Nakamura, H. Nakasa, I. Ishii, N. Ariyoshi, T. Igarashi, S. Ohmori, and M. Kitada Effects of Endogenous Steroids on CYP3A4-Mediated Drug Metabolism by Human Liver Microsomes Drug Metab. Dispos., May 1, 2002; 30(5): 534 - 540. [Abstract] [Full Text] [PDF] |
||||